TARS Earnings Prediction
The chart below shows how TARS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TARS sees a +1.01% change in stock price 10 days leading up to the earnings, and a -2.63% change 10 days following the report. On the earnings day itself, the stock moves by +0.39%. This data can give you a slight idea of what to expect for the next quarter's release.
TARS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
48.12M
2471.78%
17.90%
Gross Margin
93.26%
16.79%
0.67%
Operating Margin
-52.29%
-97.61%
-35.92%
Net Margin
-48.67%
-97.67%
-40.33%
EPS
-0.61
-52.34%
-30.68%
No Data Available
TARS Earnings Analysis
Tarsus Pharmaceuticals, Inc. Common Stock Corporation (TARS.O) Earnings Conference Call
Positive
XDEM VY Sales Performance: In the fourth full quarter of our launch, we generated more than $48 million in XDEM VY net product sales driven by more than 41,400 bottles delivered to patients impacted by demodex blepharitis or DB.
Sales Force Expansion Impact: We expanded our sales force from approximately 100 to 150 at the end of the third quarter, and we are starting to see a meaningful increase in the number of eye care professionals, or ECPs prescribing XDEM VY as well as the number of ECPs who write multiple times a week, leading indicators that depth of prescribing is trending in the right direction.
Cash and Marketable Securities: We ended the third quarter with $317 million in cash and marketable securities.
Prescription Growth Expectations: We expect continued growth in XDEM VY prescriptions with more frequent visits to our ECPs and patients working to maximize their insurance plan benefits before they reset in 2025.
Coverage Milestone Achievement: We ended the third quarter with over 80% of lives covered, a remarkable statistic this early in the launch.
Negative
Strongest Quarter Performance: Q3 marked our strongest quarter to date, highlighted by $48.1 million in extending net product sales, more than 41,400 bottles dispensed to patients, a gross net discount of approximately 40% and securing additional commercial and the two larger remaining Medicare payer contracts.
Operating Expenses Overview: Total operating expenses were approximately $73.3 million for the third quarter of 2024 and remained relatively flat, inclusive of the expanded sales force offset by other sales and marketing costs.
Stable Gross Margins: Gross margins for the third quarter remained relatively flat at approximately 93% which includes the royalty and the amortization of any milestones we paid to Elanco.
Cash Position and Growth Outlook: We ended the third quarter with $317 million in cash and marketable securities, looking ahead to the fourth quarter, we expect continued growth in XDEM VY prescriptions with more frequent visits to our ECPs and patients working to maximize their insurance plan benefits before they reset in 2025.
Gross Net Discount Increase: We expect to see the potential for a one to two point increase in the gross net discount due to the anticipated impact from the donut hole for which we did see an increased trend in our third quarter.
TARS FAQs
How does TARS typically perform around its earnings report dates?
Is Tarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
TARS Earning Call Sentiment
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
TARS.O
-0.97%Positive
The earnings call presents a mixed outlook. Financial performance shows strong net sales and gross margins, but operating expenses remain high. Regulatory feedback in Europe is positive, but market competition and economic factors pose risks. The Q&A highlights uncertainties in sales force effectiveness and payer coverage. Despite robust liquidity, the absence of shareholder returns is a concern. Overall, the sentiment is neutral, balancing strong financials with potential challenges.
